340 related articles for article (PubMed ID: 33681816)
41. Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction.
Wang Y; Sano S; Yura Y; Ke Z; Sano M; Oshima K; Ogawa H; Horitani K; Min KD; Miura-Yura E; Kour A; Evans MA; Zuriaga MA; Hirschi KK; Fuster JJ; Pietras EM; Walsh K
JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32154790
[TBL] [Abstract][Full Text] [Related]
42. Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination.
Cakouros D; Hemming S; Gronthos K; Liu R; Zannettino A; Shi S; Gronthos S
Epigenetics Chromatin; 2019 Jan; 12(1):3. PubMed ID: 30606231
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
[TBL] [Abstract][Full Text] [Related]
44. Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Jing CB; Fu C; Prutsch N; Wang M; He S; Look AT
Leukemia; 2020 Nov; 34(11):2992-3006. PubMed ID: 32572188
[TBL] [Abstract][Full Text] [Related]
45. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.
Meisel M; Hinterleitner R; Pacis A; Chen L; Earley ZM; Mayassi T; Pierre JF; Ernest JD; Galipeau HJ; Thuille N; Bouziat R; Buscarlet M; Ringus DL; Wang Y; Li Y; Dinh V; Kim SM; McDonald BD; Zurenski MA; Musch MW; Furtado GC; Lira SA; Baier G; Chang EB; Eren AM; Weber CR; Busque L; Godley LA; Verdú EF; Barreiro LB; Jabri B
Nature; 2018 May; 557(7706):580-584. PubMed ID: 29769727
[TBL] [Abstract][Full Text] [Related]
46. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
[TBL] [Abstract][Full Text] [Related]
47. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
48. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
49. Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils.
Huerga Encabo H; Aramburu IV; Garcia-Albornoz M; Piganeau M; Wood H; Song A; Ferrelli A; Sharma A; Minutti CM; Domart MC; Papazoglou D; Gurashi K; Llorian Sopena M; Goldstone R; Fallesen T; Wang Q; Ariza-McNaughton L; Wiseman DH; Batta K; Gupta R; Papayannopoulos V; Bonnet D
Cell Stem Cell; 2023 Jun; 30(6):781-799.e9. PubMed ID: 37267914
[TBL] [Abstract][Full Text] [Related]
50. Tet2 at the interface between cancer and immunity.
Jiang S
Commun Biol; 2020 Nov; 3(1):667. PubMed ID: 33184433
[TBL] [Abstract][Full Text] [Related]
51. High frequency of clonal hematopoiesis in Erdheim-Chester disease.
Cohen Aubart F; Roos-Weil D; Armand M; Marceau-Renaut A; Emile JF; Duployez N; Charlotte F; Poulain S; Lhote R; Hélias-Rodzewicz Z; Della-Valle V; Bernard O; Maloum K; Nguyen-Khac F; Donadieu J; Amoura Z; Abdel-Wahab O; Haroche J
Blood; 2021 Jan; 137(4):485-492. PubMed ID: 33067622
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
53. B-cell tumor development in
Mouly E; Ghamlouch H; Della-Valle V; Scourzic L; Quivoron C; Roos-Weil D; Pawlikowska P; Saada V; Diop MK; Lopez CK; Fontenay M; Dessen P; Touw IP; Mercher T; Aoufouchi S; Bernard OA
Blood Adv; 2018 Mar; 2(6):703-714. PubMed ID: 29581109
[TBL] [Abstract][Full Text] [Related]
54. [TET2 gene in hematological diseases].
Li S; Wang XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):836-41. PubMed ID: 24989305
[TBL] [Abstract][Full Text] [Related]
55. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
56. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
57. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
58. Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells.
Putiri EL; Tiedemann RL; Thompson JJ; Liu C; Ho T; Choi JH; Robertson KD
Genome Biol; 2014 Jun; 15(6):R81. PubMed ID: 24958354
[TBL] [Abstract][Full Text] [Related]
59. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
